Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Thromb Haemost ; 98(3): 635-41, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17849053

RESUMEN

Review of literature has shown an increased rate of thrombotic complications in diabetic patients with frequent episodes of hyperketonemia. However, the mechanisms by which ketosis promotes vascular disease in diabetic patients are unclear. It was the aim of this study to investigate early changes in haemostatic parameters and oxidative stress markers during the hyperketonemic status which follows the interruption of continuous subcutaneous insulin infusion (CSII) in type I diabetic patients. Eight CSII-treated type I diabetic patients underwent a 4-hour pump arrest. Blood glucose, insulin and 3-hydroxybutirate were measured to verify the metabolic response. A vein-occlusive (VO) test was performed for the determination of tPA and PAI-1 activities and their antigen levels before and after the CSII arrest. Coagulation factor VII and VIII were evaluated by one-stage PT and PTT method, respectively. TF, vWF, tPA and PAI-1 antigens were determined by ELISA, whereas tPA and PAI-1 activities using chromogenic methods. Plasma malondialdehyde (MDA) and protein carbonyl groups (PCG) levels were determined by HPLC and spectrophotometry, respectively. After the insulin deprivation phase, post-VO tPA antigen level significantly decreased (P = 0.0391), whereas TF and post-VO PAI-1 activity and antigen levels significantly increased (P = 0.0156 and P = 0.0234, respectively). Plasma MDA and PCG levels were 1.88-fold and 1.74-fold higher than baseline values, respectively. In conclusion, the impairment of the fibrinolytic potential and the increases in TF, MDA and PCG levels may enhance the risk of both arterial and venous thrombosis during ketosis. Thus, early detection of hyperketonemia in DM patients could contribute to the prevention of life-threatening vascular events.


Asunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Cetoacidosis Diabética/complicaciones , Endotelio Vascular/metabolismo , Fibrinólisis , Hipoglucemiantes/administración & dosificación , Insulina/administración & dosificación , Estrés Oxidativo , Trombosis/etiología , Adulto , Pruebas de Coagulación Sanguínea , Glucemia/metabolismo , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 1/metabolismo , Cetoacidosis Diabética/sangre , Cetoacidosis Diabética/etiología , Cetoacidosis Diabética/metabolismo , Esquema de Medicación , Factor VII/metabolismo , Factor VIII/metabolismo , Femenino , Humanos , Hipoglucemiantes/sangre , Inyecciones Subcutáneas , Insulina/sangre , Sistemas de Infusión de Insulina , Masculino , Malondialdehído/sangre , Persona de Mediana Edad , Inhibidor 1 de Activador Plasminogénico/sangre , Carbonilación Proteica , Tromboplastina/metabolismo , Trombosis/sangre , Trombosis/metabolismo , Factores de Tiempo , Activador de Tejido Plasminógeno/sangre , Factor de von Willebrand/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...